Glepaglutide is a long-acting analog of glucagon-like peptide-2 (GLP-2), developed by Zealand Pharma for short bowel syndrome. The European Union authorised it as Zeydovio on November 12, 2026. In the United States, the FDA asked for another trial, and that trial is recruiting. Sources were checked on November 17, 2026.
Quick answer: Glepaglutide is approved in the EU but not in the US. The FDA issued a Complete Response Letter in December 2024 and recommended another placebo-controlled trial. Zealand’s EASE-5 trial is recruiting to provide that evidence. Only one of the two regimens tested in EASE-1 beat placebo.
Vitrapep does not sell glepaglutide; this page is a reference summary of published research and regulatory information.
What is glepaglutide?
Glepaglutide is a linear peptide of 39 amino acids. PubChem describes it as a “mutated human glucagon like peptide-2 (GLP-2) analogue with a C-terminal hexa-lysine addition.” Its sequence is HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK, with an amidated end (PubChem CID 146170995). The first 33 residues are a modified GLP-2 sequence, and six lysines follow.
PubChem lists the formula C197H325N53O55, a molecular weight of 4,316 g/mol and the code name ZP1848. It counts as a peptide because it is a single chain of amino acids. Zealand describes it as “a long-acting GLP-2 analog that is stable in aqueous solution” (Zealand Pharma, 2025). Our guide to peptide half-life explains why long action matters.
Glepaglutide: key facts
| Fact | Detail |
|---|---|
| Structure type | Linear peptide of 39 amino acids: modified GLP-2 sequence plus six C-terminal lysines |
| Class | Long-acting GLP-2 receptor agonist |
| Molecular formula | C197H325N53O55 |
| Molecular weight | 4,316 g/mol |
| Development stage | US: phase 3 trial EASE-5 recruiting (2026) after a December 2024 Complete Response Letter |
| Sponsor or developer | Zealand Pharma |
| Approved outside the US | European Union, as Zeydovio, November 12, 2026 |
How does glepaglutide work?
EMA describes GLP-2 as “a natural hormone that helps maintain the structure and function of the intestine.” Glepaglutide attaches to GLP-2 receptors in the intestine, the same target as teduglutide. According to EMA, this promotes growth of the intestinal lining and increases its thickness and surface area. It also increases intestinal blood flow and slows movement through the gut, so more fluid and nutrients can be absorbed (EMA, 2026).
In patients, success is measured as a drop in parenteral support, meaning nutrition and fluids that bypass the gut. A 2020 laboratory comparison found glepaglutide “less potent and less selective” at the receptor than native GLP-2, apraglutide or teduglutide (Hargrove et al., 2020). Laboratory potency alone does not predict clinical results.
What is glepaglutide being studied for?
Glepaglutide is not approved by the FDA for any use. Outside the US, the EU issued a marketing authorisation for Zeydovio on November 12, 2026. The European Medicines Agency states that “Zeydovio is indicated for the treatment of adults with Short Bowel Syndrome (SBS).” Patients should be stable after a period of intestinal adaptation following surgery (EMA, 2026). The medicine is under additional monitoring.
ClinicalTrials.gov lists these phase 3 studies in short bowel syndrome, all sponsored by Zealand Pharma:
- EASE SBS 1: 106 patients, completed 2022, results posted (NCT03690206);
- EASE SBS 2: long-term study, 150 patients, completed April 2026 (NCT03905707);
- EASE SBS 3: extension, 84 patients, completed April 2026 (NCT04881825);
- EASE SBS 5: randomized, placebo-controlled, about 90 patients, recruiting since February 2026 (NCT07197944); and
- EASE SBS 6: 28 patients, active and not recruiting (NCT07228403).
What did the key trials show?
EASE-1. This international, randomized, double-blind, placebo-controlled phase 3 trial enrolled 106 adults with SBS and intestinal failure. All needed parenteral support at least 3 days a week. Patients were randomized 1 to 1 to 1 to two glepaglutide regimens or placebo, with results at week 24 (Jeppesen et al., 2025).
With one regimen, weekly parenteral support volume fell by 5.13 L, versus 2.85 L with placebo (P = .0039). The other regimen did not differ significantly from placebo. For the effective regimen, clinical response was 65.7% vs 38.9% (P = .0243). Response meant at least a 20% cut in weekly volume at weeks 20 and 24. A cut of at least one day a week was seen in 51.4% vs 19.4% (P = .0043). Five patients (14%) stopped needing parenteral support entirely, compared with none on placebo.
The FDA decision. Zealand reports that the New Drug Application included EASE-1 as its single placebo-controlled phase 3 trial. In the December 2024 Complete Response Letter, the FDA recommended an additional placebo-controlled trial. Its purpose is to confirm efficacy and safety of the regimen Zealand intends to market (Zealand Pharma, 2025). These are human data.
What side effects have studies reported?
EASE-1 posted adverse event results on ClinicalTrials.gov. Serious adverse events affected 9 and 10 of 35 patients in the two glepaglutide groups, and 7 of 36 on placebo. No deaths were reported. The most frequent other events, glepaglutide groups vs placebo, were (NCT03690206):
- local reactions where the drug was given: 9 and 15 vs 1;
- abdominal pain: 5 and 6 vs 2;
- redness where the drug was given: 5 and 6 vs 1;
- nausea: 7 and 3 vs 1;
- headache: 4 and 3 vs 3; and
- vomiting: 3 and 6 vs 0.
The trial publication described glepaglutide as safe and well tolerated. EMA lists the most common side effects of Zeydovio, which may affect more than 1 in 10 people. They include local reactions where the drug is given, stoma problems, abdominal pain, nausea and vomiting. Fluid retention and abdominal swelling or bloating are also listed (EMA, 2026).
What is glepaglutide’s regulatory status, and how is it used in research?
In the United States, glepaglutide is investigational. FDA designated it an orphan drug for “Treatment of short bowel syndrome” on October 20, 2017. The sponsor is Zealand Pharma A/S, and the status reads “Not FDA Approved for Orphan Indication” (FDA orphan database). Zealand expects EASE-5 to provide further confirmatory evidence for a US submission.
In the EU, Zeydovio is an authorised medicine from November 12, 2026, with Zealand Pharma A/S as holder. In research, glepaglutide is a reference point in studies comparing GLP-2 analogs. For research-labeled compounds versus approved drugs, see research use only, explained.
Frequently asked questions about glepaglutide
Is glepaglutide a peptide?
Yes. It is a 39-amino-acid GLP-2 analog with six lysines added at one end.
Is glepaglutide FDA approved?
No. The FDA issued a Complete Response Letter in December 2024, and the EASE-5 trial is recruiting.
Is glepaglutide approved anywhere?
Yes. The EU issued a marketing authorisation for Zeydovio (glepaglutide) on November 12, 2026, for adults with short bowel syndrome.
How does glepaglutide compare with teduglutide and apraglutide?
All three act on the GLP-2 receptor. Teduglutide has its own approved status, while apraglutide is still in phase 3. No head-to-head human trial was found.
What did EASE-1 show?
One regimen cut weekly parenteral support by 5.13 L versus 2.85 L with placebo. The other regimen did not differ significantly.
What to know now
- Structure: 39 amino acids; modified GLP-2 plus six lysines; 4,316 g/mol.
- EU: authorised as Zeydovio on November 12, 2026.
- US: not FDA-approved; Complete Response Letter in December 2024.
- Evidence: one EASE-1 regimen cut parenteral support 5.13 L vs 2.85 L per week.
- Safety: local site reactions, abdominal pain and nausea were frequent; no deaths.
- Next: EASE-5 phase 3 recruiting about 90 patients.
What we’re watching
EASE-5 progress, with primary completion estimated for October 2028. Publication of the full Zeydovio product information on EMA’s site and any US resubmission. Related guides: apraglutide, teduglutide and larazotide acetate.